

## P-Glycoprotein (ABCB1) Antibody (Center) Blocking peptide

Synthetic peptide Catalog # BP6111a

# **Specification**

### P-Glycoprotein (ABCB1) Antibody (Center) Blocking peptide - Product Information

**Primary Accession** 

P08183

# P-Glycoprotein (ABCB1) Antibody (Center) Blocking peptide - Additional Information

**Gene ID 5243** 

#### **Other Names**

Multidrug resistance protein 1, ATP-binding cassette sub-family B member 1, P-glycoprotein 1, CD243, ABCB1, MDR1, PGY1

## **Target/Specificity**

The synthetic peptide sequence used to generate the antibody <a href=/product/products/AP61112>AP6112>AP61112>AP61

href=/product/products/AP6111a>AP6111a</a> was selected from the Center region of human ABCB1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

### P-Glycoprotein (ABCB1) Antibody (Center) Blocking peptide - Protein Information

Name ABCB1 (HGNC:40)

Synonyms MDR1, PGY1

### **Function**

Translocates drugs and phospholipids across the membrane (PubMed:<a

href="http://www.uniprot.org/citations/8898203" target="\_blank">8898203</a>, PubMed:<a href="http://www.uniprot.org/citations/2897240" target="\_blank">2897240</a>, PubMed:<a href="http://www.uniprot.org/citations/9038218" target="\_blank">9038218</a>, PubMed:<a href="http://www.uniprot.org/citations/35970996" target="\_blank">35970996</a>). Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins (PubMed:<a

href="http://www.uniprot.org/citations/8898203" target=" blank">8898203</a>).



Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells (PubMed:<a href="http://www.uniprot.org/citations/2897240" target="\_blank">2897240</a>, PubMed:<a href="http://www.uniprot.org/citations/9038218" target="\_blank">9038218</a>, PubMed:<a href="http://www.uniprot.org/citations/35970996" target="\_blank">35970996</a>).

#### **Cellular Location**

Cell membrane; Multi-pass membrane protein {ECO:0000255|PROSITE-ProRule:PRU00441} Apical cell membrane. Cytoplasm Note=ABCB1 localization is influenced by C1orf115 expression levels (plasma membrane versus cytoplasm). Localized to the apical membrane of enterocytes (PubMed:28408210).

#### **Tissue Location**

Expressed in small intestine (PubMed:28408210). Expressed in liver, kidney and brain.

## P-Glycoprotein (ABCB1) Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

# • Blocking Peptides

P-Glycoprotein (ABCB1) Antibody (Center) Blocking peptide - Images

## P-Glycoprotein (ABCB1) Antibody (Center) Blocking peptide - Background

The membrane-associated ABCB1 protein is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance. ABCB1 is an ATP-dependent drug efflux pump for xenobiotic compounds with broad substrate specificity. It is responsible for decreased drug accumulation in multidrug-resistant cells and often mediates the development of resistance to anticancer drugs. This protein also functions as a transporter in the blood-brain barrier.

# P-Glycoprotein (ABCB1) Antibody (Center) Blocking peptide - References

Saito, S., et al., J. Hum. Genet. 47(1):38-50 (2002). Kerb, R., et al., Pharmacogenomics 2(1):51-64 (2001). Cascorbi, I., et al., Clin. Pharmacol. Ther. 69(3):169-174 (2001). Hoffmeyer, S., et al., Proc. Natl. Acad. Sci. U.S.A. 97(7):3473-3478 (2000). Mickley, L.A., et al., Blood 91(5):1749-1756 (1998).